...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.
【24h】

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.

机译:最初和随后的非黑素瘤皮肤癌:新西兰肾移植受者人群的发病率和预测指标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Renal transplant recipients (RTRs) have an increased risk of developing nonmelanoma skin cancers (NMSCs). The aims of this study were to determine the incidence and subsequent history of NMSCs in RTRs, together with risk factors. METHODS: All patients transplanted between July 1972 and March 2007, and followed up at Christchurch Hospital, New Zealand, were studied. Immunosuppression regimens were mostly prednisone, azathioprine, cyclosporine and prednisone, mycophenolate mofetil, cyclosporine since 1998. RESULTS: Of 384 RTRs, 96 developed at least one NMSC. The median time to first NMSC was 18.3 years (95% CI 14.2, 22.9) from transplant, as estimated by survival analysis. Individual predictors of first NMSC in RTRs were older age at first transplant (P < 0.0001), male sex (P = 0.006) and initial immunosuppression regimen (P = 0.001); only age (P < 0.0001) and male gender (P = 0.003) were significant predictors in a joint model. The mean rate of subsequent NMSCs was 1.67 per year (95% CI = 1.32, 2.11). Older age at first renal transplant (P = 0.009) or at discovery of the first NMSC (P = 0.01) was associated with a higher annual rate of new NMSC following the discovery of the first NMSC. The median survival time to a second NMSC was 2.2 years (CI 1.4, 3.0). Fourteen patients died of metastatic squamous cell carcinoma (15% case fatality). CONCLUSIONS: NMSCs are a major health issue for RTRs, especially in older males. Once RTRs have developed their first NMSC, ongoing surveillance and prompt treatment are essential.
机译:背景:肾移植受体(RTRs)患非黑素瘤皮肤癌(NMSCs)的风险增加。这项研究的目的是确定RTR中NMSC的发生率和随后的病史,以及危险因素。方法:研究了1972年7月至2007年3月之间所有移植患者,并在新西兰基督城医院进行了随访。自1998年以来,免疫抑制方案主要为泼尼松,硫唑嘌呤,环孢素和泼尼松,霉酚酸酯,环孢素。结果:在384个RTR中,有96个发展了至少一种NMSC。根据生存分析估计,首次移植NMSC的中位时间为移植后的18.3年(95%CI 14.2,22.9)。 RTRs中第一个NMSC的个体预测因素是第一次移植时年龄较大(P <0.0001),男性(P = 0.006)和初始免疫抑制方案(P = 0.001);在联合模型中,只有年龄(P <0.0001)和男性(P = 0.003)是重要的预测指标。以后的NMSC的平均发生率为每年1.67(95%CI = 1.32,2.11)。发现第一个NMSC后,首次肾脏移植(P = 0.009)或发现第一个NMSC(P = 0.01)的年龄较大与新的NMSC的年率较高相关。到第二个NMSC的中位生存时间为2.2年(CI 1.4,3.0)。 14名患者死于转移性鳞状细胞癌(15%的病死率)。结论:NMSC是RTR的主要健康问题,尤其是在老年男性中。一旦RTR建立了他们的第一个NMSC,就必须进行持续的监视和及时治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号